Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
CARMIEL, Israel, May 01, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2017 financial results and provide a corporate update on Wednesday, May 10, 2017 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
